Jodi is a healthcare executive, leader, innovator, advisor and serial entrepreneur. She has more than 20 years experience in clinical development, scientific and regulatory strategy, management and medtech market development from start-ups to S&P 500 companies. Prior to founding Hawthorne Effect, Inc., Jodi was Global VP Clinical Affairs at Edwards Lifesciences, LLC- where she led the seminal clinical trials and regulatory approvals for transcatheter heart valve therapy. Also a humanitarian, Jodi led international healthcare initiatives including Heart To Heart International Children's Medical Alliance, The Nahapetov Friendship Foundation and the China Heart Group, a joint venture with the United Nations Industrial Development Organization. She holds an undergraduate degree in Foreign Service from Georgetown University, Masters in Physiology and Nursing from Pace University, New York and 8 patents with a few more pending.
Sharon Knight is the most recent addition to our executive team, having joined the company in July 2016. Sharon brings to HE diverse finance, operating and leadership experience. Having started her career in commercial banking, Sharon subsequently assumed senior finance roles at KFC Corporation, Gap Inc., and Electronic Arts (EA). In 2005, she transitioned into Operations, creating EA’s global development shared services organization and developing an internal customer ethos. In 2009, she left gaming for healthcare, becoming President of venture capital backed One Medical Group, transforming patient experience in primary care, and growing it from 4 to 16 locations in 3 markets. Since 2012, she has also been an active digital health/health IT angel investor and board member through her own Avik Ventures. Sharon holds an MBA in Finance from Kellogg Graduate School of Management and a BA in Economics from Smith College.
John has extensive experience in design, development, and management. He started his career at SRI International and then became a founding member of Oracle’s first Multimedia Department. In 1993, John joined Apple Computer as a producer, designer, and developer of family entertainment software. He later served as Senior Producer at Shockwave.com and as Director of Content Development at Organic, where he managed high-profile projects for Intel, Barnes and Noble, and others. He went on to found a design and development firm whose clients included Disney, LeapFrog, George Lucas, The Smithsonian, UCSF, the Library of Congress, and others. John was CTO for Jeff Katz’s Travel Game, where he helped build the first social game world on Google Earth. He studied software design at the MIT Media Lab and earned his Masters in educational technology from Harvard University. John holds bachelors degrees in Biology and English from Stanford University.
Bill brings to HE a broad set of skills in the design, development, and management of software products. Bill began his career as a producer at Apple’s Multimedia Lab, where he designed and developed seminal products for WGBH, Lucas Learning, the Exploratorium, and the American Federation of Teachers. He went on to found True North Studios, where he developed several award-winning products for clients such as the Library of Congress, the Smithsonian Air & Space Museum, Kaiser Permanente, and McGraw-Hill. In 2004, Bill founded a design and development company whose clients included Apple Computer, Disney, Harvard, Ford, UCSF, Houghton Mifflin, and many others. He was VP of Design and Development for Jeff Katz’s Travel Game, where he helped develop innovative games on the Google Earth platform. Bill received an EdM in Educational Technology from the Harvard Graduate School of Education and a BA in Cognitive Psychology from Northwestern University.
Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Bio-Technology. Rich has raised approximately a billion dollars for companies, and he has directly influenced and participated in over a billion dollars in acquisition events.
Mr. Ferrari has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. CardioThoracic Systems (CTS), which Rich co-founded was sold for $350 million with a return of 20x for the venture investors. Rich was the force and strategic architect that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Rich also co-founded the Medical Technology Group which spun-out Integrated Vascular Systems, acquired by Abbott Vascular for $100 million and Ensure, acquired by J&J, for $100 million, each of these companies returned 10x to the venture investors.
Previously Mr. Ferrari held the positions of Executive Vice President and General Manager of ADAC Laboratories. In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to startup medical technology companies.
Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.
Aran Ron is a physician trained in internal medicine at New York Hospital. He is one of the original founders and until recently the Chief Medical Officer of Oscar Health Plan and of Pager. He is the former President and Chief Operating Officer of Group Health Inc., a $3 billion health plan, was Medical Director at Oxford Health Plan and at New York Downtown Hospital. He served as CEO of Partners Health Plan (a special needs MLTC plan) and an Operating Partner at Bessemer Venture Partners. His background includes board certification and licensure in internal medicine, degrees in business and public health. He has published articles in medical journals, and serves on local and national committees, and on the board of director’s and advisory boards including Group Health Inc (term ended 3/12), formerly Data Driven Delivery Systems, Nalari, Dunn Meadow Pharmacy, Israel BioMed Fund, LifeForce Capital Fund as well as not-for-profits St Christopher Inc and Metropolitan Council on Poverty. He is on the URAC accreditation committee and lectures at Cornell Medical College (where he received a best teacher of the year award) and Columbia Business School.
Bray Patrick-Lake supports efforts to actively engage patients, health advocacy organizations, and other stakeholders in Duke University’s local and national research programs. She has led extensive efforts through the Clinical Trials Transformation Initiative to incorporate patient voice in clinical trial design, conduct, oversight, and regulatory frameworks, as well as improvement of the clinical trial enterprise. Most recently she co-chaired the Advisory Committee to the NIH Director’s Working Group responsible for authoring the vision and roadmap to launch the Precision Medicine Initiative Cohort Program. She served as the Interim Director of Engagement for several months after program launch. She currently serves on the Precision Medicine Initiative National Advisory Panel and leads engagement work at Duke’s Coordinating Center for NIH’s Environmental Influences on Child Health Outcomes (ECHO) program.
In 2010, Ms. Patrick-Lake founded the Patent Foramen Ovale (PFO) Research Foundation in response to the lack of definitive scientific information regarding the condition of PFO after being a patient in an aborted device clinical trial. Ms. Patrick-Lake has served as a patient representative at the FDA on a variety of advisory committees and panels, in workgroups for EMA, NIH, and NAM/IOM, and as a patient stakeholder or co-investigator for Agency for Healthcare Research and Quality and Patient-Centered Outcomes Research Institute grants. She was a member of the PCORnet Coordinating Center's Executive Leadership Committee where she developed patient engagement strategies and has served on the MDEpiNet’s National Medical Device Registry Task Force, the Medical Device Innovation Consortium’s Patient-centered Benefit-Risk Steering Committee, American College of Cardiology (ACC) Foundation's Patient-centered Care Shared Decision Making and Patient-generated Health Data working groups, and ACC Transcatheter Valve Therapy Registry Stakeholder Advisory Committee.
Thomas R. Fleming, PhD, is Professor and former Chair of the Department of Biostatistics at the University of Washington in Seattle, Member of the Fred Hutchinson Cancer Research Center, and the former Director of the Statistical Center for HIV/AIDS Prevention Trial Network, NIAID. Dr. Fleming received his BA in 1972 from the University of St. Thomas and his MA in 1974 and PhD in 1976 from the University of Maryland, College Park.
Dr Fleming has authored or coauthored several books and more than 250 research articles in peer-reviewed journals, many regarding the development of state of the art methods for the design, conduct and analysis of clinical trials, and many others reporting the results of landmark trials, including the 2011 publication in NEJM on prevention of transmission of HIV. This research, on which he was senior author, was recognized by Science Magazine to be the scientific “Breakthrough of the Year”.
He has chaired or served on Data Monitoring Committees for more than 100 clinical trials. He is a Special Government Employee for the FDA, and for 30 years he has served as a regular member of several FDA Advisory Committees and as an invited voting member on more than 100 occasions.
Dr Fleming has received numerous awards. He is recipient of the Outstanding Teaching Award, School of Public Health from the University of Washington, and the FDA Commissioner’s Special Citation Award for Extraordinary Contribution to the Agency. He is the 2007 Greenberg Lecturer at University of North Carolina, the 2009 Distinguished Lecturer at the School of Public Health at the University of Washington and, in 2011, the Ross Prentice Endowed Professor of Biostatistical Collaboration. In 2012, he was elected to membership in the Institute of Medicine of the National Academies.
Martin B. Leon, MD, is a Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy (CIVT) at NewYork-Presbyterian Hospital/Columbia University Medical Center. Previously, Dr. Leon was also the Director of the Cardiac Catheterization Laboratories at NewYork-Presbyterian Hospital/Columbia University Medical Center and currently he serves on the Executive Board of the NewYork-Presbyterian/Columbia Heart Valve Center. Dr. Leon was the Founder and Chairman Emeritus of the Cardiovascular Research Foundation (CRF) in New York City and is currently CRF’s Co-Director, Medical Research and Education Division. CRF is the largest independent not-for-profit cardiovascular research center in the United States.
A distinguished pioneer in interventional cardiovascular medicine, Dr. Leon has been the national principal investigator for over 50 clinical trials that have helped shape the field including STRESS, STARS, Gamma-one, SIRIUS, ENDEAVOR, and most recently, the PARTNER trial, studying the value of transcatheter valve therapy for patients with aortic stenosis. He has co-authored almost 2,000 peer reviewed scientific publications and abstracts, which have appeared in the most prestigious medical journals. As a practicing interventional cardiologist, Dr. Leon has performed over 10,000 procedures during his career.
He is the Founder and Director of Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier scientific symposium dedicated to interventional cardiovascular medicine, which celebrated its 27th anniversary last year. He has also been the Director or Co-Director of more than 100 international educational programs in the field. Dr. Leon has received 20 international career achievement awards and was awarded an honorary degree from the University of Athens.
Dr. Leon was previously the Director of Cardiovascular Research and Education at the Lenox Hill Heart and Vascular Institute in New York as well as Director of Clinical Research at the Washington Cardiology Center at the Washington Hospital Center and Clinical Professor of Medicine at Georgetown University Medical Center in Washington, DC. He also served as a Clinical Associate, Senior Investigator, and Director of the Catheterization Laboratories in the Cardiology Branch of the National Heart, Lung and Blood Institute at the National Institutes of Health in Bethesda, Maryland. He was a founder of the Washington Cardiology Center and the Cardiology Research Foundation in Washington, DC.
Dr. Leon received his medical degree from the Yale School of Medicine and completed his internal medicine internship and residency as well as a cardiology fellowship at the Yale-New Haven Hospital.
Esther Dyson (@edyson) is executive founder of Way to Wellville, and is also an active investor in startups. Way to Wellville is a 10-year project operating in five communities (Clatsop County OR, Muskegon County MI, North Hartford CT, Lake County CA and Spartanburg SC). Its purpose is to help those communities to invest in measurable, visible improvement in their health, and to demonstrate the financial and social ROI of doing so.In the healthcare field, she sits on the boards of 23andMe and Voxiva/Wellpass, and is an investor in (among others) 23andMe, Applied Proteomics, Big Health, Clover Health, Eligible API, Enso, GeriJoy, Hawthorne Effect, Health Loop, HealthTap, i2Dx, Impact Health, Medesk, Medivo, mEquilibrium, Omada Health, PatientsLikeMe, PatientsKnowBest (UK), Proofpilot, Resilient, StartupHealth, Tocagen, Valkee (Finland), Voxiva and Zipongo.